Malaria surveillance amongst pregnant women attending antenatal care in private hospitals in Onitsha metropolis, South Eastern Nigeria

Moses N. Ikegbunam1,2,3*, Chibuzo Uba1, Judith Flügge3, Harrison Abone1, Dorothy Ezeagwuna4, Simeon Ushie5, Charles Esimone1,2

1 Department of Pharmaceutical Microbiology and Biotechnology, Nnamdi Azikiwe University, Awka, Nigeria; 2 Molecular Research Foundation for Students and Scientists, Nnamdi Azikiwe University, Awka, Nigeria; 3 Institute for Tropical Medicine, Tübingen, Germany; 4 Department of Parasitology and Entomology, Nnamdi Azikiwe University, Awka, Nigeria; 5 Department of Medical Microbiology and Parasitology, Nnamdi Azikiwe University, Awka, Nigeria. *email: mn.ikegbunam@unizik.edu.ng, nmnkechukwu@gmail.com

**Background.** Recent reports suggest that pregnant women living in holoendemic regions of sub-Saharan Africa die in great numbers annually due to malaria disease resulting from their higher susceptibility, reduced immunity and demographic associated factors. This work investigated the prevalence of *Plasmodium falciparum* in pregnant women attending antenatal care (ANC) in selected private hospitals in Onitsha metropolis South East Nigeria.

**Methods.** Venous blood samples were collected from 270 pregnant women during ANC visits between October 2016 and December 2017. A questionnaire was used to collect demographic data, gestational age, knowledge of malaria and preventive measures while clinical presentations and symptoms were extracted from the physician’s clerking form. Laboratory diagnosis was done using microscopy. The effect of the demographic variables and other associated factors on prevalence and parasite densities was studied using Chi-square and ANOVA tests.

**Results.** The overall *P. falciparum* prevalence was 42.6%. Prevalence varied with the maternal age, gestational age, preventive measures adopted by the pregnant women and clinical presentations. 27.8% of the infected women were highly parasitized (>5000 parasites/µl); 67% had a moderate parasite density (1,000-4,999 parasites/µl) and 5.2% showed a low parasite density (1-999 parasites/µl). We observed that 35.2%, 30%, 18.9% and 5.2% of the study cohorts preferred and used treated bed nets, insecticides, windows and door screening and non-treated bed nets respectively as malaria preventive measures. 5.9% did not use any protection.

**Conclusions.** The findings of this study revealed high prevalence of malaria among pregnant women living in Onitsha metropolis with high mean parasite densities despite strong adherence to use of sulphadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) and other malaria preventive measures.

**INTRODUCTION**

Malaria disease is considered a major public health concern among pregnant women especially in tropical and subtropical areas of the world and in sub-Saharan Africa, where malaria vectors are commonly found. Malaria in pregnancy results in adverse pregnancy outcomes, such as spontaneous abortion, neonatal death, and low birth weight. Chronic anemia, due to malaria may also affect a child’s growth and intellectual development. Pregnant women are particularly vulnerable to malaria infection as a result of reduced immunity [1].

In malaria-endemic regions of Africa, pregnancies are threatened by malaria. Recently, prevalence of exposure to malaria during pregnancy was highest in Central Africa (40%), closely followed by West Africa (39%), while East and Southern Africa had a reported exposure prevalence of 24% [2]. Pregnant women residing in areas with stable malaria transmission are at a greater risk of serious malaria. Pregnant women in such places are at a greater risk of serious malaria than non-pregnant women, and therefore face a higher mortality rate due to malaria [3,4].
Nigeria contributes more malaria than other endemic regions in Africa, with 27% and 23% of global malaria cases and global malaria deaths respectively [2]. Following these reports and other available data in the literature, malaria is holoendemic in many parts of Nigeria with transmission occurring throughout the year [1]. These increases the vulnerability of pregnant women, since there is an increased likelihood of infection due to perennial transmission. The transmission of malaria is affected by many environmental and socio-economic factors, including sanitation, housing, literacy and poverty, among others [5]. Furthermore, WHO has linked malaria to poverty, because it is believed to more severely affect the less privileged in society that cannot afford to pay for malaria treatment [6]. WHO has once listed Onitsha in Anambra State as one of the most polluted cities and like many other endemic regions facing the same challenge, it is exposed to high transmission of malaria parasites [7].

Due to the fact that pregnant women have greater vulnerability and decreased immunity, many malaria control programmes are concerned about their safety especially those residing in malaria-endemic nations, so there is need for regular updated information on the prevalence of malaria among pregnant women, especially in endemic areas. A review of the existing literature over the last decade revealed only a few publications that documented the prevalence of malaria among pregnant women in Onitsha [8,9,10]. Therefore, this study assessed the prevalence of *P. falciparum* among pregnant women attending ANC in selected private hospitals in Onitsha metropolis as well as the impact of control strategies on their respective parasite densities.

**Study area**

Onitsha is located in Anambra State and lies between Latitudes 06005120.8911N and 06013126.47311N and Longitude 06045120.60411E and 06052110.57311E. It is situated on the eastern side of the River Niger and covers approximately 50 square kilometers [11]. The average annual rainfall in Onitsha is approximately 1,850 millimeter with varying annual temperature ranging from 23˚C to 37˚C [11]. Onitsha is a business area having the biggest market in West Africa.

**Study design**

This was a cross-sectional study with a sample size of 270 pregnant women (calculated using Cochran equation described by Anto et al. [12]) scheduled for ANC visits.

Participants with clinical diagnosis of fever (temperature >37.5˚C) and/or a history of fever, and headache as reported by the physician, were included. Socio-demographic data were captured using a pre-tested questionnaire. Ethical clearance was obtained from the UNTH Ethical Board (Reference No. approval number: NHREC/05/01/2008B-FWA00002458-IRB00002323). Written informed consent was obtained from all study participants.

**Sample collection and microscopy**

Between October 2016 and December 2017, about 2 ml of venous blood was collected into anti-coagulant containers from pregnant women that attended the ANC. Samples were analysed and examined by a WHO-certified microscopist using a standard procedure [13]. Blood specimens collected in EDTA bottles were used to make thick and thin films on a microscope slide. The films were stained with 10% Giemsa stain (pH 7.2) for 10 min and then viewed under an oil immersion objective of a microscope (at 1,000x magnification). Parasitaemia was calculated using the formula recommended by WHO [14] as follows:

\[
\text{Parasite Density} = \left(\frac{\text{Number of Parasites counted}}{\text{WBC counted}}\right) \times \text{Assumed WBC count}
\]

Samples were labeled negative if no parasites were detected after observing 200 fields of a thick blood film.

**Data presentation and analysis**

All data were presented and calculated using SPSS statistical package (version 22). The effect of the demographic variables and other associated factors
on prevalence and parasite densities was studied using Chi-square and ANOVA tests, respectively, with a significance level of $p \leq 0.05$ and confidence level of 95%.

RESULTS

Demographic characteristics

The demographic characteristics of the 270 women as captured by the questionnaire are shown in Table 1. Most of the participants (37.8%) fell into the age group of 27-32 yrs. The study population had a mean age of 27.41±5.56 yrs. The majority of participants (40.7%) were in their 2nd trimester and had enjoyed secondary education (47.8%).

Malaria prevention

Nearly half of the participants (48.9%) had used SP for prophylaxis against malaria infection prior to participation in the study; nearly a third (29.4%) had not received any prophylaxis. Some participants used quinine (8%), amodiaquine (0.4%) or artemether-lumefantrine (AL) (13%), which are not usually recommended for use during pregnancy. The use of insecticide-treated bed nets and insecticides (indoor residual spraying) was higher (35.8% and 30.6%, respectively) than any other vector control measure adopted by the women.

Clinical signs and symptoms

Clinical presentations as recorded on the ANC cards by doctors and nurses were extracted and are shown in Table 1. Asymptomatic women represented 34.8% of the total population. Additionally, 34.4% of the women presented with headache and fever. Fewer women reported only headache (24.1%) or only fever (6.7%).

P. falciparum prevalence

Microscopy confirmed 115 of the blood samples as positive, giving an overall prevalence of 42.6% (Table 1). Parasite densities were calculated for the positive slides and categorized, showing that 27.8% had high parasitaemias (>5,000 parasites/µl), 67% of moderate (1,000-4,999 parasites/µl) and 5.2% had a low parasite parasitaemia (1-999 parasites/µl). P. falciparum prevalence with respect to age, gestational age, prophylaxis using SP, vector control measures and clinical symptoms is shown in Table 1 while the effect of these associated risk factors on parasite density is presented in Table 2.

Prevalence decreased with age. The highest prevalence (60.9%) was observed in the youngest age cohort (15-20 yrs). In contrast, 27-32 yrs group had the lowest prevalence (39.2%; $p>0.05$) (Table 1). Mean parasite density for the 15-20 yrs cohort ($6053±7664$ parasite/µl) was higher than those for the other age groups. Mean parasite densities decreased with age although these observed differences were not significant (Table 2).

The frequency of parasite occurrence was high (48.20%) among pregnant women in their 1st trimester (1-3 months) than among those in 2nd (4-6 months) and 3rd trimesters (42.70% and 35.90% respectively) (Table 1) at $p>0.05$. Women in their 1st trimester had a higher mean parasite density of 4463±3162 parasite/µl, compared to those in 2nd and 3rd trimesters who had a mean parasite density (parasite/µl) of 4283±4827 and 3861±2594 respectively ($p>0.05$) (Table 2).

The prevalence of P. falciparum infection decreased with increasing level of education among pregnant women (Table 1). Those who only had primary education had the highest prevalence rate (62.5%) compared with those who had secondary (44.20%) and tertiary education (36.50%) at $p>0.05$. The mean parasite density was higher in those women whose highest level of education was a secondary education ($5068±5068$ parasite/µl) compared to those with primary education ($3517±2490$ parasite/µl) and tertiary education ($3402±2286$ parasite/µl) at $p>0.05$ (Table 2).

The prevalence rate of P. falciparum was higher among pregnant women who used quinine (57.9%) than those who had used AL (50%) and SP (48.7) at $p<0.05$ (Table 1). However, the mean parasite density was higher among those who had not received prophylaxis ($6342±6269$ parasites/µl) compared to those who have used SP ($4212±2893$ parasites/µl) and AL ($3427±1871$ parasites/µl) at $p>0.05$ (Table 2).
It was further observed that the prevalence rate of *P. falciparum* was higher among pregnant women who used non-treated bed nets (64.30%) than among those who used windows and door nets (43.10%), treated bed nets (42.10%) and insecticides (IRS) (39.50%). The observed difference was not statistically significant at p<0.05.

The distribution of parasite density with respect to the type of malaria prevention method used by the pregnant women participating in the study is shown in Table 2. Mean parasite density was higher in those who used non-treated bed nets (5617±3221 parasites/µl) compared to others who used windows and door nets (4508±4579 parasites/µl), treated bed nets (4314±4474 parasites/µl), insecticides (IRS) (4082±2853 parasites/µl) or insecticides and others (4152±2749 parasites/µl) at p>0.05.

The prevalence rate of *P. falciparum* among pregnant women with respect to the clinical symptoms was higher among those with headache and fever (78.50%) than in asymptomatic individuals who recorded only 16.10% of the *P. falciparum* infections. Furthermore, the mean parasite density was higher in those who indicated headache and fever (4931±4301 parasites/µl) compared to those who indicated headache only (3764±1949 parasites/µl) or fever only (3644±3284 parasites/µl). Among the asymptomatic individuals, the mean parasite density was considerably low (1847±1319 parasites/µl). The observed effect was statistically significant at p<0.05 (Table 2).

**DISCUSSION**

Malaria remains a serious public health challenge across Africa and Nigeria in particular. It is detrimental to the health of pregnant women and their unborn child [15]. In this study, we determined *P. falciparum* prevalence among pregnant women who visited private hospitals for ANC in Onitsha Anambra state, Nigeria.

Malaria prevalence was found to be high. This may be attributed to a several factors ranging from increased attractiveness to mosquitoes [16] to immunological and physiological changes required for the survival of the fetus [15]. Also, environmental factors such as blockage of drainage systems, large population of people living in poor housing as well as high environmental pollution posing a serious challenge to people living in Onitsha metropolis as documented by WHO [7] can create a good breeding habitat for mosquitoes and hence the increased prevalence rate observed in this study. This finding is consistent with some recent reports of high malaria prevalence rates among pregnant women attending ANC units across Nigerian states [17].

A high prevalence rate of *P. falciparum* and parasite density was observed among young pregnant women compared to older pregnant women. Even though this was not statistically significant, many studies have attributed this observation to lower immunity of younger pregnant women against malaria [15,18]. Through frequent and repeated malaria infections, older pregnant women produce more antibodies to malaria parasites and therefore gain higher immunity than younger pregnant women protecting them against generation of high parasite densities below detectable levels and clinical symptoms [18]. This corresponds to previous investigations which demonstrated that malaria is more common among younger pregnant women [17,19]. This study revealed that the prevalence rate of *P. falciparum* and parasite density decreased nonsignificantly with increase in gestational age. It is expected that parasite load should be higher in the third trimester compared to first and second trimester, due to progressive immunomodulation in pregnancy, a state needed for fetal survival wherein the mother’s systemic immune reaction is altered towards the humoral arm, significantly noticed in the third trimester than the first [20]. This deviation could be due to improved understanding and use of malaria control strategies like treated bed nets and alternative intermittent preventive treatment with SP among the study participants. This observation has been reported for other similar studies in sub-Saharan Africa including South Eastern Nigeria [21-24]. The prevalence of *P. falciparum* infection and parasite density was higher among pregnant women with primary school education and secondary school education than those with tertiary education. However, the finding was not statistically significant. The use of antimalarial drugs significantly affected the prevalence but not
the distribution of parasite density among the study participants. This finding, like other previous reports, suggests that the use of intermittent preventive treatment with IPTp-SP or AL as indicated in this study were apparently effective at malaria prevention and treatment as it resulted to a reduced parasite density among the pregnant women who used them [25,26].

Also, *P. falciparum* prevalence and density was higher among those who used non-treated bednets compared to the prevalence rate and density obtained among those who used treated bednets and other preventive measures even though no statistically significant difference was observed. Majority of the participants preferred the use of insecticide-treated bednets as a prevention measure more than other preventive measures, and this may have contributed to a lower observed malaria prevalence. In Nigeria, insecticide treated bednets have been reported to be an effective measure of preventing malaria. Ownership and use of long-lasting insecticidal nets (LLIN) are proven interventions adopted by Roll Back Malaria (RBM) partners in Nigeria to stem the high incidence of malaria [27].

However, both prevalence and mean parasite density was higher in symptomatic pregnant women than among the asymptomatic individuals. This suggests that the symptoms and clinical presentation of malaria cases during pregnancy is significantly dependent on parasite load and can be useful for early detection. It further approves the use of clinical presentation as first line diagnosis for malaria in pregnant women and immediate treatment of patients with fever, headache, or headache and fever with antimalarial drugs, where laboratory screening and confirmation is not readily available. Treatment based on clinical presentation in pregnant women may help prevent complications associated with malaria in pregnancy as well as prevent potentially fatal disease among those living in rural settings.

Finally, a high mean parasite density was recorded contrary to the thought that pregnant women usually have reduced number of parasites in the blood circulation due to proliferation of parasites in the placenta [28,29]. High parasite densities as obtained in this study could be associated to accumulation of multiple clones and genetic diversity of *P. falciparum* parasites which gives room for parasite immune evasion including drug resistance especially in areas of high transmission [30-32]. Studies in other parts of Nigeria have shown high genetic diversity in *P. falciparum* isolates [33-36] suggesting the possibility of high transmission, drug resistance and subsequently a high parasite density among people living in this region.

**CONCLUSIONS**

The prevalence of malaria among pregnant women living in the Onitsha is considerably high. There is a strong adherence to the use of SP for IPTp among pregnant women attending ANC in selected hospitals. Also, there is a strong adherence to the use of treated bednets, and window and door screening as malaria prevention measures. Despite strong adherence to SP for IPTp and other malaria preventive measures, the findings of this study revealed a high mean parasite density among the (especially younger) study cohort. Therefore, efforts should be made towards studying and understanding the molecular basis for the reported high prevalence and parasite density among pregnant women. Malaria elimination programmes should focus on strategies that will help pregnant women in poor and highly dirty environments to understand the risk of exposure to malaria infection as well as provide access to malaria prevention measures including ITNs and LLINs so as to reduce the malaria burden in this population.

**ACKNOWLEDGEMENTS**

The authors are grateful to the TETFund for their PhD bench work support for the current study and to the study participants for consenting to participate in this study. Also, we are thankful to Terence Sambe for proof reading the manuscript with much meaningful input. The first author received PhD bench work support from TETFund.

**COMPETING INTERESTS**

The authors declare that they have no competing interests.
Table 1. Prevalence of *P. falciparum* in pregnant women (n=270) with respect to demographic variables, prophylaxis, vector control measures and clinical presentations.

| Variables                      | n   | Microscopy |
|--------------------------------|-----|------------|
|                                |     | Negative (%) | Positive (%) | P-value |
| **Age group (years)**          |     |             |              |        |
| 15-20                          | 23  | 9 (39.1)    | 14 (60.9)    |        |
| 21-26                          | 101 | 61 (60.4)   | 40 (39.6)    |        |
| 27-32                          | 102 | 62 (60.8)   | 40 (39.2)    |        |
| 33-38                          | 35  | 18 (51.4)   | 17 (48.6)    |        |
| >38                            | 9   | 5 (55.6)    | 4 (44.4)     |        |
| **Total**                      | 270 | 155 (57.4)  | 115 (42.6)   | 0.341  |
| **Gestation age (months)**     |     |             |              |        |
| 1-3                            | 82  | 42 (51.2)   | 40 (48.8)    |        |
| 4-6                            | 110 | 63 (57.3)   | 47 (42.7)    |        |
| 7-9                            | 78  | 50 (64.1)   | 28 (35.9)    |        |
| **Total**                      | 270 | 155 (57.4)  | 115 (42.6)   | 0.257  |
| **Education**                  |     |             |              |        |
| Primary                        | 24  | 9 (37.5)    | 15 (62.5)    |        |
| Secondary                      | 129 | 72 (55.8)   | 57 (44.2)    |        |
| Tertiary                       | 115 | 73 (63.5)   | 42 (36.5)    |        |
| **Total**                      | 268 | 154 (57.5)  | 114 (42.5)   | 0.056  |
| **Antimalaria drug used**      |     |             |              |        |
| Amodiaquine                    | 1   | 1 (100)     | 0 (0)        |        |
| AL*                            | 30  | 15 (50)     | 15 (50)      |        |
| Quinine                        | 18  | 8 (42.1)    | 11 (57.9)    |        |
| SP**                           | 113 | 58 (51.3)   | 55 (48.7)    |        |
| None                           | 68  | 51 (75)     | 17 (25)      |        |
| **Total**                      | 181 | 109 (60.2)  | 72 (39.8)    | 0.009  |
| **Vector control measures**    |     |             |              |        |
| Window / door screens          | 51  | 29 (56.9)   | 22 (43.1)    |        |
| Treated nets                   | 95  | 55 (57.9)   | 40 (42.1)    |        |
| Untreated nets                 | 14  | 5 (35.7)    | 9 (64.3)     |        |
| Insecticides                   | 81  | 49 (60.5)   | 32 (39.5)    |        |
| Insecticides and others        | 8   | 5 (62.5)    | 3 (37.5)     |        |
| No protection                  | 16  | 10 (62.5)   | 6 (37.5)     |        |
| **Total**                      | 265 | 153 (57.1)  | 112 (42.3)   | 0.658  |
| **Clinical symptoms**          |     |             |              |        |
| Headache                       | 65  | 49 (75.4)   | 16 (24.6)    |        |
| Headache and fever             | 93  | 20 (21.5)   | 73 (78.5)    |        |
| Fever                          | 18  | 7 (38.9)    | 11 (61.1)    |        |
| **Total**                      | 269 | 154         | 115 (42.8)   | ≤0.001 |

* AL = Artemether-lumefantrine; ** SP = Sulphadoxine- pyrimethamine
Table 2. Effect of demographic variables, gestational age, preventive measures, prophylaxis and clinical symptoms on mean parasite densities (MPD±SD) in pregnant women (n=270).

| Variables                        | n   | MPD±SD     | P-value |
|----------------------------------|-----|------------|---------|
| **Age group (years)**            |     |            |         |
| 15-20                            | 15  | 6053 ± 7664|         |
| 21-26                            | 40  | 4291 ± 2436|         |
| 27-32                            | 40  | 3814 ± 3089|         |
| 33-38                            | 17  | 4078 ± 1396|         |
| >38                              | 4   | 2419 ± 1396|         |
| **Total**                        | 115 |            | 0.33    |
| **Gestation age (months)**       |     |            |         |
| 1-3                              | 40  | 4463 ± 3162|         |
| 4-6                              | 47  | 4283 ± 4827|         |
| 7-9                              | 28  | 3861 ± 2594|         |
| **Total**                        | 115 |            | 0.81    |
| **Education**                    |     |            |         |
| Primary                          | 15  | 3517 ± 2490|         |
| Secondary                        | 57  | 5068 ± 5068|         |
| Tertiary                         | 43  | 3402 ± 2286|         |
| **Total**                        | 115 |            | 0.68    |
| **Vector control measures**      |     |            |         |
| Window/ door screens             | 22  | 4308 ± 4579|         |
| Treated nets                     | 40  | 4314 ± 4474|         |
| Untreated nets                   | 9   | 5617 ± 3221|         |
| Insecticides                     | 32  | 4082 ± 2853|         |
| Insecticides and others          | 3   | 4152 ± 2749|         |
| No Protection                    | 6   | 2501 ± 2270|         |
| **Total**                        | 112 |            | 0.77    |
| **Antimalaria drug use**         |     |            |         |
| AL*                              | 15  | 3427 ± 1871|         |
| Quinine                          | 11  | 5353 ± 5626|         |
| SP**                             | 55  | 4212 ± 2893|         |
| None                             | 17  | 6342 ± 6269|         |
| **Total**                        | 98  |            | 0.14    |
| **Clinical symptoms**            |     |            |         |
| Asymptomatic                     | 15  | 1847 ± 1318|         |
| Headache                         | 16  | 3764 ± 1949|         |
| Headache and Fever               | 73  | 4931 ± 4301|         |
| Fever                            | 11  | 3644 ± 3284|         |
| **Total**                        | 115 |            | 0.03    |

* AL: Artemether-lumefantrine; ** SP: Sulphadoxine- pyrimethamine
REFERENCES

1. Dokunmu TM, Adjeukor CU, Yakubu OF, Bello AO et al.: Asymptomatic malaria infections and Pfmdr1 mutations in an endemic area of Nigeria. Malar. J. 2019, 18:218. Doi:10.1186/s12936-019-2833-8

2. World Health Organization: World Malaria Report 2019. World Health Organization, 2020.

3. Takem EN, D’Alessandro U: Malaria in pregnancy. Mediterr. J. Hematol. Infect. Dis. 2013, 5:e2013010. Doi:10.4084/mjhid.2013.010

4. Cutts JC, Agius PA, Lin Z, Powell R et al.: Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review. BMC Med. 2020, 18:14. Doi:10.1186/s12916-019-1467-6

5. Dieng CC, Gonzalez L, Pestana K, Dhikrullahi SB et al.: Contrasting asymptomatic and drug resistance gene prevalence of Plasmodium falciparum in Ghana: implications on seasonal malaria chemoprevention. Genes 2019, 10:538. Doi:10.3390/genes10070538

6. World Health Organization: World Malaria Report 2015. World Health Organization, 2016.

7. World Health Organization: WHO global urban ambient air pollution database (update 2016). World Health Organization, 2016. https://www.who.int/phe/health_topics/outdoorair/databases/cities/en/

8. Iwueze MO, Okwusogu MI, Onyido AE, Okafor FC et al.: Prevalence intensity and clinical profile of malaria among pregnant women attending antenatal clinics in Onitsha-North local government area Anambra State southern Nigeria. The Bioscientist 2014, 2:17-29. https://bioscientistjournal.com/index.php/TheBioscientist/article/view/66

9. Nnanna AD, Chinyeaka EP, Benedicta AO, Fidelia EO et al.: Malaria prevalence the use of intermittent preventive therapy and long lasting insecticidal nets among pregnant women in Onitsha Anambra State Nigeria. Int. J. Trop. Dis. Health 2015, 8:144-149.

10. Ukibe SN, Ukibe NR, Mbanugo JL, Ikeakor LC: Prevalence of malaria among pregnant women attending antenatal clinics in hospitals in Anambra State south-east Nigeria. Niger. J. Parasitol. 2016, 37:240-244. Doi:10.4314/njprire.v37i2.21

11. UN-Habitat: Nigeria; onitsha urban profile (E Miller ed.). Nairobi Kenya, United Nations Human Settlements Programme (UN-Habitat), 2012, pp 1-164.

12. Anto F, Agongo IH, Asoala V, Awini E et al.: Intermittent preventive treatment of malaria in pregnancy: assessment of the Sulfadoxine-Pyrimethamine three-dose policy on birth outcomes in rural northern Ghana. J. Trop. Med. 2019, Article ID 6712685:1-10. Doi:10.1155/2019/6712685

13. Cheesbrough M: District laboratory practice in tropical countries part 1 and 2. Cambridge low price editions 2nded United States of America, 2020 Cambridge University Press.

14. World Health Organization: Guidelines for the treatment of malaria 3rd edn. World Health Organization, 2015.

15. Gontie GB, Wolde HE, Baraki AG: Prevalence and associated factors of malaria among pregnant women in Sherkole district Benishangul Gumuz regional state West Ethiopia. BMC Infect. Dis. 2020, 20:1-8. Doi:10.1186/s12879-020-05289-9

16. Gonçalves BP, Walker PG, Cairns M, Tiono AB et al.: Pregnant women: an overlooked asset to Plasmodium falciparum malaria elimination campaigns? Trends Parasitol. 2017, 33:510-518. Doi:10.1016/J.PT.2017.03.001

17. Yakubu DP, Kamji NB, Dawet A: Prevalence of malaria among pregnant women attending antenatal care at Faith Alive Foundation Jos Plateau State. Noble Int. J. Sci. Soc. Res. 2018, 2:19-26. https://EconPapers.repec.org/RePEc:njp:ijssr:2018:p:19:26

18. McLean ARD, Ataide R, Simpson JA, Beeson JG et al.: Malaria and immunity during pregnancy and postpartum: a tale of two species. Parasitology 2015, 142:999-1015. Doi:10.1017/S0031182015000074

19. Mbah JO, Njoku OO, Nnachi AU, Nnachi IA et al.: Incidence of antenatal malaria parasitaemia and the effects on the haemoglobin profile of pregnant women in Enugu East Local Government area Enugu Nigeria. Amer. J. Epidemiol. Infect. Dis. 2015, 3:88-94.

20. Sykes L, MacIntyre DA, Yap XJ, Ponnampalam S et al.: Changes in the Th1: Th2 cytokine bias in pregnancy and the effects of the anti-inflammatory cyclopentanone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2. Mediat. Inflamm. 2012, Article ID 416739. Doi:10.1155/2012/416739

21. Mayor A, Bardají A, Macete E, Nhampossa T et al.: Changing trends in P. falciparum burden immunity and disease in pregnancy. N. Engl. J. Med. 2015, 373:1607-1617. Doi:10.1056/NEJMoa1406459

22. Kotoh AM, Boah M: “No visible signs of pregnancy no sickness no antenatal care”: initiation of antenatal care in a rural district in Northern Ghana. BMC Public Health 2019, 19:1-13. Doi:10.1186/s12889-019-7400-2

23. Nwaneri AC, Ndubuisi I, Okoronkwo IL, Ezike O et al.: Determinants of late booking for antenatal care among pregnant women in selected hospitals in South East Nigeria. Int. J. Nurs. Midwifery 2018, 10:74-80. Doi:10.5897/IJNM2018.0308

24. Fana SA, Danladi M, Bunza A, Anka SA et al.: Prevalence and risk factors associated with malaria infection among pregnant women in a semi-urban community of north-western Nigeria. Infect. Dis. Poverty 2015, 4:24. Doi:10.1186/s40249-015-0054-0
25. Abamecha A, Yilma D, Adissu W, Yewhalaw D et al.: Efficacy and safety of artemether–lumefantrine for treatment of uncomplicated *Plasmodium falciparum* malaria in Ethiopia: a systematic review and meta-analysis. *Malar. J.* 2021, 20:1-14. Doi:10.1186/s12936-021-03745-8

26. White NJ: Malaria parasite clearance. *Malar. J.* 2017, 16:1-14. Doi:10.1186/s12936-017-1731-1

27. Israel OK, Fawole OI, Adebowale AS, Ajayi IO et al.: Caregivers' knowledge and utilization of long-lasting insecticidal nets among under-five children in Osun State southwest Nigeria. *Malar. J.* 2018, 17:231. Doi:10.1186/s12936-018-2383-5

28. Odorizzi PM, Jagannathan P, McIntyre TI, Budker R et al.: In utero priming of highly functional effector T cell responses to human malaria. *Sci. Transl. Med.* 2018, 10: e6176. Doi:10.1126/scitranslmed.aat6176

29. Mathison BA, Pritt BS: Update on malaria diagnostics and test utilization. *J. Clin. Microbiol.* 2017, 55:2009-2017. Doi:10.1128/JCM.02562-16

30. Amoah LE, Nuvor SV, Oboh EK, Acquah FK et al.: Natural antibody responses to *Plasmodium falciparum* MSP3 and GLURP (R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana. *Parasit. Vectors* 2017, 10:1-9. Doi:10.1186/s13071-017-2338-7

31. Lamptey H, Ofori MF, Kusi KA, Adu B et al.: The prevalence of submicroscopic *Plasmodium falciparum* gametocyte carriage and multiplicity of infection in children pregnant women and adults in a low malaria transmission area in Southern Ghana. *Malar. J.* 2018, 17:1-12. Doi:10.1186/s12936-018-2479-y

32. Mayengue PI, Ndounga M, Malonga FV, Bitemo M et al.: Genetic polymorphism of merozoite surface protein-1 and merozoite surface protein-2 in *Plasmodium falciparum* isolates from Brazzaville Republic of Congo. *Malar. J.* 2011, 10:1-7. Doi:10.1186/1475-2875-10-226

33. Nguetse CN, Ojo JA, Nchotebah C, Ikegbunam MN et al.: Genetic diversity of the *Plasmodium falciparum* glutamate-rich protein R2 region before and twelve years after introduction of artemisinin combination therapies among febrile children in Nigeria. *Am. J. Trop. Med. Hyg.* 2018, 98:667–676. Doi:10.4269/ajtmh.17-0621

34. Yakubu B, Longdet IY, Jen TH, Davou DT et al.: High-complexity *Plasmodium falciparum* infections North Central Nigeria 2015-2018. *Emerg. Infect. Dis.* 2019, 25:1330–1338. Doi:10.3201/eid2507.181614

35. Fagbemi KA, Adebusuyi SA, Nderu D, Adedokun SA et al.: Analysis of sulphadoxine–pyrimethamine resistance-associated mutations in *Plasmodium falciparum* isolates obtained from asymptomatic pregnant women in Ogun State southwest Nigeria. *Infect. Genet. Evol.* 2020, 85:e104503. Doi:10.1016/j.meegid.2020.104503

36. Ajogbasile FV, Kayode AT, Olunyoi PE, Akano KO et al.: Genetic diversity and population structure of *Plasmodium falciparum* in Nigeria: insights from microsatellite loci analysis. *Malar. J.* 2021, 20:1-9. Doi:10.1186/s12936-021-03734-x